Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 12 of the 13 references it cites were found in a registry or an index; 6 of the 18 sources its claims cite were checked for support.

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

Open access

Abstract

KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent inhibitor of KRAS G12C, was recently approved for the treatment of KRAS G12C-mutated non-small cell lung cancer (NSCLC). However, the efficacy of sotorasib and other KRAS G12C inhibitors is limited by intrinsic resistance in colorectal cancer (CRC) and by the rapid emergence of acquired resistance in all treated tumors. Therefore, there is an urgent need to develop novel combination therapies to overcome sotorasib resistance and to maximize its efficacy. We assessed the effect of sotorasib alone or in combination with DT2216 (a clinical-stage BCL-X L proteolysis targeting chimera [PROTAC]) on KRAS G12C-mutated NSCLC, CRC and pancreatic cancer (PC) cell lines using MTS cell viability, colony formation and Annexin-V/PI apoptosis assays. Furthermore, the therapeutic efficacy of sotorasib alone and in combination with DT2216 was evaluated in vivo using different tumor xenograft models. We observed heterogeneous responses to sotorasib alone, whereas its combination with DT2216 strongly inhibited viability of KRAS G12C tumor cell lines that partially responded to sotorasib treatment. Mechanistically, sotorasib treatment led to stabilization of BIM and co-treatment with DT2216 inhibited sotorasib-induced BCL-X L/BIM interaction leading to enhanced apoptosis in KRAS G12C tumor cell lines. Furthermore, DT2216 co-treatment significantly improved the antitumor efficacy of sotorasib in vivo. Collectively, our findings suggest that due to cytostatic activity, the efficacy of sotorasib is limited, and therefore, its combination with a pro-apoptotic agent, i.e., DT2216, shows synergistic responses and can potentially overcome resistance.

Overview

CoChat Summary

TL;DR

DT2216, a clinical-stage BCL-XL PROTAC degrader, synergizes with sotorasib in KRASG12C-mutated NSCLC, colorectal cancer, and pancreatic cancer cell lines and xenografts by disrupting sotorasib-induced BCL-XL/BIM interaction and enhancing apoptosis. The combination improved antitumor efficacy over sotorasib monotherapy in preclinical models, supporting clinical testing particularly in KRASG12C-mutated CRC.

Key findings

  • DT2216 at 1 µM completely depleted BCL-XL in KRASG12C-mutated cancer cell lines; sotorasib alone showed heterogeneous and only partial viability reduction in sensitive lines, while sotorasib + DT2216 synergistically reduced viability, inhibited colony formation, and induced apoptosis in partially sensitive H358 NSCLC, MIA PaCa-2 PC, and SW837 CRC lines.
  • Synergy was caspase-mediated: the pan-caspase inhibitor QVD-OPh significantly abrogated the sotorasib + DT2216 effect; inhibition of BCL-XL, but not BCL-2 or MCL-1, sensitized the three partially sensitive cell lines to sotorasib.
  • Mechanistically, sotorasib upregulated BIM and BMF, decreased p-BIM (S69), and increased BCL2L11; sotorasib selectively induced BCL-XL/BIM interaction, which was disrupted by DT2216-mediated BCL-XL degradation.
  • In xenografts, DT2216 (15 mg/kg q4d i.p.) plus sotorasib (10 mg/kg 5 days/week p.o.) significantly inhibited tumor growth versus sotorasib monotherapy in H358, MIA PaCa-2, and SW837 models (n = 7–8 mice/group), with no significant body-weight change or clinically significant blood-count decrease.

Methods

  • In vitro: KRASG12C-mutated H358 NSCLC, MIA PaCa-2 PC, and SW837 CRC cell lines, plus non-KRASG12C-mutated lines; assays included MTS viability, colony formation, Annexin-V/PI apoptosis, immunoblot, and immunoprecipitation.
  • In vivo: H358, MIA PaCa-2, and SW837 xenograft models treated with vehicle, DT2216, sotorasib, or combination; tumor volume, BCL-XL densitometry, and IHC for Ki67 and cleaved caspase-3 were assessed.
  • Statistics: one-way ANOVA with Tukey’s multiple comparison test and two-sided Student’s t-test; viability data from n = 6 replicate cell cultures, xenograft data from n = 7–8 mice at treatment start, and densitometry from n = 4 mice/group.

Limitations

  • The paper states no explicit limitations section.
  • Evident from the text: all findings are preclinical, using cell lines and mouse xenografts only, with no clinical validation; safety is limited to mouse body weights and blood cell counts.
  • Evident from the text: synergy was observed only in cell lines partially sensitive to sotorasib, while non-KRASG12C-mutated and non-responding KRASG12C lines did not respond to the combination; the study does not directly model acquired sotorasib resistance in vivo.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13045-022-01241-3

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 A combination of sotorasib and DT2216 has synergistic antitumor activity through suppression of BCL-XL/BIM interaction in KRASG12C-mutated cancer cell lines. a Viability of KRASG12C-mutated H358 NSCLC, MIA PaCa-2 PC and SW837 CRC cell lines after they were treated with increasing concentrations of sotorasib (Sot) in threefold increments with either DMSO or DT2216 (DT, 1 µM) for 72 h. The data are presented as percentage viability relative to control (mean ± SD; n = 6 replicate cell cultures) as measured by MTS assay. b CDI values were calculated at different concentrations of Sot used in combination with 1 µM of DT, and their averages are shown in the table for H358, MIA PaCa-2 and SW837 cell lines. CDI < 0.7 indicates significant synergistic effect. CDI < 1 indicates synergistic effect, CDI = 1 indicates additive effect, and CDI > 1 indicates antagonistic effects. EC50, half-maximal effective concentration (equivalent to IC50 or half-maximal inhibitory concentration); CDI, coefficient of drug interaction. c colony formation in indicated cell lines after they were treated with DT (1 µM), Sot (0.1 µM), or a combination of the two (Combo) for 10–14 days followed by crystal violet staining. d Apoptosis in the cell lines after they were treated with indicated concentrations of Sot with either DMSO or DT (1 µM) for 48 h (H358) or 72 h (MIA PaCa-2 and SW837). The data are presented as percentage Annexin V+ (apoptotic) cells in total cell population (mean ± SEM) as measured by Annexin V/PI staining using flow cytometry. Statistical significance was determined by one-way ANOVA and Tukey’s multiple comparison test. *p < 0.05, **p < 0.01, ***p < 0.001. ns, not significant. e–g Immunoblot analysis of BCL-XL, BIM, BMF and PUMA in H358 (e), MIA PaCa-2 (f) and SW837 (g) cell lines after they were treated with indicated concentrations of Sot with either DMSO or DT (1 µM) for 24 h. Immunoblots detect three isoforms of BIM, i.e., short isoform (BIMS), long isoform (BIML) and extra-long isoform (BIMEL). Among them, BIMEL is the major isoform and is shown here. Densitometry graphs of selected immunoblots normalized to equal loading control β-tubulin are shown in Additional file 1: Fig. 8a-c. h–j Immunoprecipitation analysis of BCL-XL in H358 (h), MIA PaCa-2 (i) and SW837 (j) cell lines after they were treated with Sot (0.1 µM), DT (1 µM) or Combo for 24 h, and the immunoprecipitated as well as input samples were subjected to immunoblot analysis of BIM, BMF, PUMA and BCL-XL. β-tubulin was used as an equal loading control
Fig. 1 A combination of sotorasib and DT2216 has synergistic antitumor activity through suppression of BCL-XL/BIM interaction in KRASG12C-mutated cancer cell lines. a Viability of KRASG12C-mutated H358 NSCLC, MIA PaCa-2 PC and SW837 CRC cell lines after they were treated with increasing concentrations of sotorasib (Sot) in threefold increments with either DMSO or DT2216 (DT, 1 µM) for 72 h. The data are presented as percentage viability relative to control (mean ± SD; n = 6 replicate cell cultures) as measured by MTS assay. b CDI values were calculated at different concentrations of Sot used in combination with 1 µM of DT, and their averages are shown in the table for H358, MIA PaCa-2 and SW837 cell lines. CDI < 0.7 indicates significant synergistic effect. CDI < 1 indicates synergistic effect, CDI = 1 indicates additive effect, and CDI > 1 indicates antagonistic effects. EC50, half-maximal effective concentration (equivalent to IC50 or half-maximal inhibitory concentration); CDI, coefficient of drug interaction. c colony formation in indicated cell lines after they were treated with DT (1 µM), Sot (0.1 µM), or a combination of the two (Combo) for 10–14 days followed by crystal violet staining. d Apoptosis in the cell lines after they were treated with indicated concentrations of Sot with either DMSO or DT (1 µM) for 48 h (H358) or 72 h (MIA PaCa-2 and SW837). The data are presented as percentage Annexin V+ (apoptotic) cells in total cell population (mean ± SEM) as measured by Annexin V/PI staining using flow cytometry. Statistical significance was determined by one-way ANOVA and Tukey’s multiple comparison test. *p < 0.05, **p < 0.01, ***p < 0.001. ns, not significant. e–g Immunoblot analysis of BCL-XL, BIM, BMF and PUMA in H358 (e), MIA PaCa-2 (f) and SW837 (g) cell lines after they were treated with indicated concentrations of Sot with either DMSO or DT (1 µM) for 24 h. Immunoblots detect three isoforms of BIM, i.e., short isoform (BIMS), long isoform (BIML) and extra-long isoform (BIMEL). Among them, BIMEL is the major isoform and is shown here. Densitometry graphs of selected immunoblots normalized to equal loading control β-tubulin are shown in Additional file 1: Fig. 8a-c. h–j Immunoprecipitation analysis of BCL-XL in H358 (h), MIA PaCa-2 (i) and SW837 (j) cell lines after they were treated with Sot (0.1 µM), DT (1 µM) or Combo for 24 h, and the immunoprecipitated as well as input samples were subjected to immunoblot analysis of BIM, BMF, PUMA and BCL-XL. β-tubulin was used as an equal loading controlCC BY · PubMed Central
Fig. 2 BCL-XL degradation with DT2216 enhances the antitumor efficacy of sotorasib in KRASG12C-mutated xenograft models. a–c Tumor volume changes in H358 (a), MIA PaCa-2 (b) and SW837 (c) xenografts after they were treated with vehicle, DT2216 (DT, 15 mg/kg, every four days [q4d], i.p.), sotorasib (Sot, 10 mg/kg, 5 days a week, p.o.) or a combination of the two (Combo). Data are presented as mean ± SEM (n = 7–8 mice at the start of treatment). Statistical significances in a–c were determined by two-sided Student’s t-test at day-41, day-25 and day-25 in H358, MIA PaCa-2 and SW837 xenografts, respectively. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. d–f Changes in tumor volumes of individual mice in H358 (d), MIA PaCa-2 (e) and SW837 (f) xenografts at the end of treatment calculated as: tumor volume at the end of treatment − baseline tumor volume. g–i Densitometric analysis showing BCL-XL protein levels as determined by immunoblotting in H358 (g), MIA PaCa-2 (h) and SW837 (i) xenograft tumors at the end of treatments as in a–c (n = 4 mice per group). The representative immunoblots are shown in Additional file 1: Fig. 12a
Fig. 2 BCL-XL degradation with DT2216 enhances the antitumor efficacy of sotorasib in KRASG12C-mutated xenograft models. a–c Tumor volume changes in H358 (a), MIA PaCa-2 (b) and SW837 (c) xenografts after they were treated with vehicle, DT2216 (DT, 15 mg/kg, every four days [q4d], i.p.), sotorasib (Sot, 10 mg/kg, 5 days a week, p.o.) or a combination of the two (Combo). Data are presented as mean ± SEM (n = 7–8 mice at the start of treatment). Statistical significances in a–c were determined by two-sided Student’s t-test at day-41, day-25 and day-25 in H358, MIA PaCa-2 and SW837 xenografts, respectively. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. d–f Changes in tumor volumes of individual mice in H358 (d), MIA PaCa-2 (e) and SW837 (f) xenografts at the end of treatment calculated as: tumor volume at the end of treatment − baseline tumor volume. g–i Densitometric analysis showing BCL-XL protein levels as determined by immunoblotting in H358 (g), MIA PaCa-2 (h) and SW837 (i) xenograft tumors at the end of treatments as in a–c (n = 4 mice per group). The representative immunoblots are shown in Additional file 1: Fig. 12aCC BY · PubMed Central

Verification

Claims the paper makes

3 Valid · 1 Not valid · 4 Not checked · 29 Own results and interpretations

22 more claims

Create a free account to see all 37 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 8
  • Probably not a substantial claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 13 references

Cited by

See all 64

Metadata

Authors
Khan, S., Wiegand, J., Zhang, P., Hu, W., Thummuri, D., Budamagunta, V., Hua, N., Jin, L., Allegra, C. J., Kopetz, S. E., Zajac-Kaye, M., Kaye, F. J., Zheng, G., & Zhou, D.
Affiliations
  • University of Florida (US)
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
  • Khan, Sajid
  • Zhou, Daohong
Venue
Journal of Hematology & Oncology
Published
2022-03-09
Volume
15
Issue
1
Pages
23-23
ISSN
1756-8722 (ISSN-L)
OpenAlex
W4221046553
Cited by
62
References
13
Citations by year
2026: 8 · 2025: 19 · 2024: 12 · 2023: 15 · 2022: 8
FWCI
4.40
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Hematology & Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Cancer Institute (R01 CA242003)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
sotorasib, KRAS G12C, apoptosis, combination therapy, acquired drug resistance, non-small cell lung cancer, colorectal cancer, pancreatic cancer, tumor xenografts, KRAS inhibitors
MeSH terms
Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Piperazines, Pyridines, Pyrimidines, Proto-Oncogene Proteins p21(ras), bcl-X Protein, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers. https://app.cochat.ai/papers/10.1186/s13045-022-01241-3
The paper
Khan, S., Wiegand, J., Zhang, P., Hu, W., Thummuri, D., Budamagunta, V., Hua, N., Jin, L., Allegra, C. J., Kopetz, S. E., Zajac-Kaye, M., Kaye, F. J., Zheng, G., & Zhou, D. (2022). BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-022-01241-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.